The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression-free survival, overall survival, and safety. RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval [CI], 15.8 to not reached), the estimated median progression-free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Self-citationOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,456
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citation
Research works printed but not linked: 1
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 1,000
Risk of hepatitis B virus reactivation in patients treated with ibrutinib
Hammond, S. P., Chen, K., Pandit, A., Davids, M. S., Issa, N. C., & Marty, F. M. (2018) · Blood · doi:10.1182/blood-2018-01-826495 · Cited by 60
Zhou, Y., Liu, W., Xu, Z., Zhu, H., Xiao, D., Su, W., Zeng, R., Feng, Y., Duan, Y., Zhou, J., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.08.012 · Cited by 61
Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches
Silkenstedt, E., Linton, K., & Dreyling, M. H. (2021) · British Journal of Haematology · doi:10.1111/bjh.17419 · Cited by 59
Self-citationKumar, A. A., Soumerai, J. D., Abramson, J. S., Barnes, J. A., Caron, P. C., Chhabra, S., Chabowska, M., Doǧan, A., Falchi, L., Grieve, C., et al. (2024) · Blood · doi:10.1182/blood.2024025563 · Cited by 59
Self-citationHarrington, B. K., Gardner, H. L., Izumi, R. E., Hamdy, A., Rothbaum, W. M., Coombes, K. R., Covey, T. M., Kaptein, A., Gulrajani, M., van Lith, B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159607 · Cited by 59
Dobie, G., Kuriri, F. A., Omar, M. M. A., Alanazi, F. G., Gazwani, A. M., Tang, C. P. S., Sze, D., Handunnetti, S. M., Tam, C. S. L., & Jackson, D. E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000640 · Cited by 61
Yue, X., Chen, Q., & He, J. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01614-z · Cited by 61
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Neys, S. F. H., Rip, J., Hendriks, R. W., & Corneth, O. B. J. (2021) · Drugs · doi:10.1007/s40265-021-01592-0 · Cited by 58
High-Dimensional Single-Cell Cancer Biology
Irish, J. M., & Doxie, D. B. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_367 · Cited by 59
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies
Ransohoff, J. D., & Kwong, B. Y. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.07.005 · Cited by 59
Targeting the B cell receptor pathway in non-Hodgkin lymphoma
Valla, K., Flowers, C. R., & Koff, J. L. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1482273 · Cited by 60
Development of BTK inhibitors for the treatment of B-cell malignancies
Kim, H.-O. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01124-1 · Cited by 60
Zanubrutinib: past, present, and future
Tam, C. S. L., Munoz, J. L., Seymour, J. F., & Opat, S. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00902-x · Cited by 58
Oellerich, T., Mohr, S., Corso, J., Beck, J., Döbele, C., Braun, H., Cremer, A., Münch, S., Wicht, J., Oellerich, M. F., et al. (2015) · Blood · doi:10.1182/blood-2014-06-585216 · Cited by 59
Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression
Kim, E., Yang, K. S., Köhler, R. H., Dubach, J. M., Mikula, H., & Weissleder, R. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00152 · Cited by 57
Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma
Dunleavy, K. M., Erdmann, T., & Lenz, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.01.002 · Cited by 57
Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
Lewis, K. L., & Cheah, C. Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080764 · Cited by 57
Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
Series, J., Garcia, C., Levade, M., Viaud, J., Siè, P., Ysebaert, L., & Payrastre, B. (2019) · Haematologica · doi:10.3324/haematol.2018.207183 · Cited by 61
Wang, M. L., Jain, P., Zhao, S., Lee, H. J., Nastoupil, L. J., Fayad, L., Ok, C. Y., Kanagal‐Shamanna, R., Hill, H. A., Yao, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00638-0 · Cited by 56
Self-citation3D based generative PROTAC linker design with reinforcement learning
Li, B., Ran, T., & Chen, H. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad323 · Cited by 57
Liu, Y., Kimpara, S., Hoang, N. M., Daenthanasanmak, A., Li, Y., Lü, L., Ngo, V. N., Bates, P. D., Song, L., Gao, X., et al. (2023) · Blood · doi:10.1182/blood.2023020142 · Cited by 56
Targeting Wnt pathway in mantle cell lymphoma-initiating cells
Mathur, R., Sehgal, L., Braun, F., Berkova, Z., Romaguera, J. E., Wang, M. L., Rodriguez, M. A., Fayad, L., Neelapu, S. S., & Samaniego, F. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0161-1 · Cited by 56
Self-citationFrom identification of the BTK kinase to effective management of leukemia
Smith, C. I. E. (2016) · Oncogene · doi:10.1038/onc.2016.343 · Cited by 57
Regan, J. A., Cao, Y., Dispenza, M. C., Ma, S., Gordon, L. I., Petrich, A. M., & Bochner, B. S. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.03.013 · Cited by 57
Dengler, M. A., Weilbacher, A., Gutekunst, M., Staiger, A. M., Vöhringer, M. C., Horn, H., Ott, G., Aulitzky, W. E., & van der Kuip, H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.552 · Cited by 57
Rudelius, M., Rosenfeldt, M. T., Leich, E., Rauert‐Wunderlich, H., Solimando, A. G., Beilhack, A., Ott, G., & Rosenwald, A. (2017) · Haematologica · doi:10.3324/haematol.2017.177162 · Cited by 57
Wang, M. L., Ramchandren, R., Chen, R., Karlin, L., Chong, G., Jurczak, W. J., Wu, K. L., Bishton, M. J., Collins, G. P., Eliadis, P. E., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01188-x · Cited by 55
Self-citationTrial watch: Tumor-targeting monoclonal antibodies for oncological indications
Vacchelli, E., Pol, J. G., Bloy, N., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H. E. K., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.985940 · Cited by 59
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
Arthurs, B. J., Wunderle, K., Hsu, M., & Kim, S. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.03.011 · Cited by 57
Cardiac Complications in the Adult Bone Marrow Transplant Patient
Tuzovic, M., Mead, M. D., Young, P. A., Schiller, G. J., & Yang, E. H. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0774-6 · Cited by 55
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
Abbas, H. A., & Wierda, W. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668162 · Cited by 54
McCulloch, R., Lewis, D. J., Crosbie, N., Eyre, T. A., Bolam, S., Arasaretnam, A., Creasey, T., Goradia, H., McMillan, A., Dawi, S., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17363 · Cited by 54
Self-citationWalter, H. S., Jayne, S., Rule, S. A., Cartron, G., Morschhauser, F., Macip, S., Karlin, L., Jones, C. H., Herbaux, C., Quittet, P., et al. (2017) · Blood · doi:10.1182/blood-2017-02-765115 · Cited by 53
Self-citationSun, S., Wu, S.-H., Kang, J.-B., Ma, Y.-Y., Chen, L., Cao, P., Chang, L., Ding, N., Xue, X., Li, N., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00030 · Cited by 54
Wang, M. L., Jurczak, W. J., Trněný, M., Belada, D., Wróbel, T., Ghosh, N., Keating, M., van Meerten, T., Alvarez, R. F., von Keudell, G., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00682-x · Cited by 53
Self-citationMurray, M. Y., Zaitseva, L., Auger, M. J., Craig, J. I. O., MacEwan, D. J., Rushworth, S. A., & Bowles, K. M. (2015) · Cell Cycle · doi:10.1080/15384101.2014.998067 · Cited by 55
Shinohara, M., Chang, B. Y., Buggy, J. J., Nagai, Y., Kodama, T., Asahara, H., & Takayanagi, H. (2013) · Bone · doi:10.1016/j.bone.2013.11.025 · Cited by 54
Self-citationBluhm, J., Kieback, E., Marino, S. F., Oden, F., Westermann, J., Chmielewski, M. M., Abken, H., Uckert, W., Höpken, U. E., & Rehm, A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.012 · Cited by 53
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
Jain, P., Dreyling, M. H., Seymour, J. F., & Wang, M. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02287 · Cited by 53
Self-citationGuo, A., Lu, P., Coffey, G., Conley, P., Pandey, A., & Wang, Y. L. (2017) · Oncotarget · doi:10.18632/oncotarget.14588 · Cited by 52
Garg, N., Padron, E., Rammohan, K. W., & Goodman, C. F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206139 · Cited by 54
Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors
Sayegh, N., Yirerong, J., Agarwal, N., Addison, D., Fradley, M. G., Cortes, J. E., Weintraub, N. L., Sayed, N., Raval, G. G., & Guha, A. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01845-2 · Cited by 52
Jiang, L., Liu, S., Jia, X., Gong, Q., Wen, X., Lu, W., Yang, J., Wu, X., Wang, X., Suo, Y., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08852 · Cited by 52
Bernard, S., Danglade, D., Gardano, L., Laguillier, C., Lazarian, G., Roger, C., Thiéblemont, C., Marzec, J., Gribben, J. G., Cymbalista, F., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29326 · Cited by 52
Next-Generation in vivo Modeling of Human Cancers
Gargiulo, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00429 · Cited by 55
Shi, X., Song, S., Ding, Z., Fan, B., Huang, W. Z., & Xu, T. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.04.031 · Cited by 52
Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia
Wu, H. Y., Hu, C., Wang, A., Weisberg, E., Chen, Y., Yun, C.-H., Wang, W., Liu, Y., Liu, X., Tian, B., et al. (2015) · Leukemia · doi:10.1038/leu.2015.180 · Cited by 52
Zhong, Y., Dong, S., Strattan, E., Ren, L., Butchar, J. P., Thornton, K., Mishra, A., Porcu, P., Bradshaw, J. M., Bisconte, A. R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.614891 · Cited by 53
Goy, A. H., Hernandez‐Ilizaliturri, F. J., Kahl, B. S., Ford, P., Protomastro, E., & Berger, M. S. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.907891 · Cited by 51
Self-citationBose, P., Gandhi, V. V., & Keating, M. J. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1239717 · Cited by 52
The molecular pathogenesis of mantle cell lymphoma
Vogt, N., Dai, B., Erdmann, T., Berdel, W. E., & Lenz, G. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1248965 · Cited by 51
SOX11 augments BCR signaling to drive MCL-like tumor development
Kuo, P.-Y., Jatiani, S., Rahman, A. H., Edwards, D., Jiang, Z., Ahr, K. F., Perumal, D., Leshchenko, V. V., Brody, J., Shaknovich, R., et al. (2018) · Blood · doi:10.1182/blood-2018-02-832535 · Cited by 51
Munakata, W., Ando, K., Hatake, K., Fukuhara, N., Kinoshita, T., Fukuhara, S., Shirasugi, Y., Yokoyama, M., Ichikawa, S., Ohmachi, K., et al. (2019) · Cancer Science · doi:10.1111/cas.13983 · Cited by 51
Pan, K., Li, Q., Guo, Z., & Li, Z. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108760 · Cited by 53
Rationale for targeting the pre–B-cell receptor signaling pathway in acute lymphoblastic leukemia
Müschen, M. (2015) · Blood · doi:10.1182/blood-2015-01-567842 · Cited by 52
Kim, E., & Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0380-3 · Cited by 51
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia
Bitar, C., Farooqui, M. Z. H., Valdez, J., Saba, N. S., Soto, S., Bray, A., Marti, G. E., Wiestner, A. U., & Cowen, E. W. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.0225 · Cited by 50
Seftel, M. D., Kuruvilla, J. G., Kouroukis, T., Banerji, V., Fraser, G. A. M., Crump, M., Kumar, R., Chalchal, H. I., Salim, M., Laister, R. C., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239259 · Cited by 50
Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma
Moffitt, A. B., & Davé, S. S. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7603 · Cited by 50
Guideline for the management of mantle cell lymphoma
McKay, P., Leach, M., Jackson, B., Robinson, S. P., & Rule, S. A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15283 · Cited by 50
Self-citationMing, M., Wu, W., Xie, B., SUKHANOVA, M. J., Wang, W., Kadri, S., Sharma, S., Lee, J., Shacham, S., Landesman, Y., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0789-atr · Cited by 50
Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
Sestier, M., Hillis, C., Fraser, G. A. M., & Leong, D. P. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01102-1 · Cited by 52
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Profitós-Pelejà, N., Santos, J. C., Marín‐Niebla, A., Roué, G., & Ribeiro, M. L. (2022) · Cancers · doi:10.3390/cancers14040860 · Cited by 53
Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases
Harbi, M. H., Smith, C. W., Nicolson, P. L. R., Watson, S. P., & Thomas, M. R. (2020) · Platelets · doi:10.1080/09537104.2020.1849600 · Cited by 53
Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
Szklener, K., Michalski, A., Żak, K., Piwoński, M., & Mańdziuk, S. (2022) · Cells · doi:10.3390/cells11081338 · Cited by 49
The B cell receptor signaling pathway in mantle cell lymphoma
Merolle, M. I., Ahmed, M., Nomie, K. J., & Wang, M. L. (2018) · Oncotarget · doi:10.18632/oncotarget.25011 · Cited by 49
Self-citationLi, Q., Cheng, L., Shen, K., Jin, H., Li, H., Cheng, Y., & Ma, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00697 · Cited by 49
Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
Yu, H., Wang, X., Li, J., Ye, Y., Wang, D., Fang, W., Mi, L., Ding, N., Wang, X., Song, Y., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.03.015 · Cited by 49
Targeted Therapies in Cancer: To Be or Not to Be, Selective
Montoya, S., Soong, D., Nguyen, N. T., Affer, M., Munamarty, S. P., & Taylor, J. (2021) · Biomedicines · doi:10.3390/biomedicines9111591 · Cited by 49
Predictive biomarkers in precision medicine and drug development against lung cancer
Fang, B., Mehran, R. J., Heymach, J. V., & Swisher, S. G. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0028-4 · Cited by 49
Self-citationNaturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies
Sommer, B. C., Dhawan, D., Ratliff, T. L., & Knapp, D. W. (2018) · Bladder Cancer · doi:10.3233/blc-170145 · Cited by 50
Vidal‐Crespo, A., Matas‐Céspedes, A., Rodríguez, V., Rossi, C., Valero, J. G., Serrat, N., Sanjuán-Pla, A., Menéndez, P. R., Roué, G., López‐Guillermo, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.211904 · Cited by 48
Rusconi, C., Cheah, C. Y., Eyre, T. A., Tucker, D. L., Klener, P., Giné, E., Crucitti, L., Muzi, C., Iadecola, S., Infante, G., et al. (2022) · Blood · doi:10.1182/blood.2022015560 · Cited by 48
Self-citationInvestigational drugs for the treatment of diffuse large B-cell lymphoma
Patriarca, A., & Gaïdano, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1855140 · Cited by 48
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies
Gayko, U., Fung, M., Clow, F., Sun, S. H., Faust, E. A., Price, S., James, D. F., Doyle, M., Bari, S., & Zhuang, S. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12878 · Cited by 52
Self-citationWu, H. Y., Wang, A., Zhang, W., Wang, B., Chen, C., Wang, W., Chen, H., Ye, Z., Zhao, Z., Wang, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5182 · Cited by 48
Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
Turetsky, A., Kim, E., Köhler, R. H., Miller, M. A., & Weissleder, R. (2014) · Scientific Reports · doi:10.1038/srep04782 · Cited by 47
Chen, R. W., Li, H., Bernstein, S. H., Kahwash, S. B., Rimsza, L. M., Forman, S. J., Constine, L. S., Shea, T. C., Cashen, A. F., Blum, K. A., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14480 · Cited by 47
Self-citationActivity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity
Hagner, P. R., Chiu, H., Ortiz, M., Apollonio, B., Wang, M., Couto, S. S., Waldman, M. F., Flynt, E., Ramsay, A. G., Trotter, M. W. B., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14866 · Cited by 48
Self-citationThe Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas
Pham, L. V., Pogue, E., & Ford, R. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00147 · Cited by 49
Current overview and treatment of mantle cell lymphoma
Schieber, M., Gordon, L. I., & Karmali, R. (2018) · F1000Research · doi:10.12688/f1000research.14122.1 · Cited by 47
Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies
da Cunha‐Bang, C., & Niemann, C. U. (2018) · Drugs · doi:10.1007/s40265-018-1003-6 · Cited by 47
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
Wang, A., Yan, X.-E., Wu, H. Y., Wang, W., Chen, H., Cheng, C., Zhao, Z., Zhao, P., Li, X., Wang, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11951 · Cited by 47
Fu, S., Wang, M. L., Lairson, D. R., Li, R., Zhao, B., & Du, X. L. (2017) · Oncotarget · doi:10.18632/oncotarget.22367 · Cited by 46
Self-citationDifferential impact of BTK active site inhibitors on the conformational state of full-length BTK
Joseph, R. E., Amatya, N., Fulton, D. B., Engen, J. R., Wales, T. E., & Andreotti, A. H. (2020) · eLife · doi:10.7554/elife.60470 · Cited by 47
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Jacobson, C., Kopp, N., Layer, J. V., Redd, R. A., Tschuri, S., Haebe, S., van Bodegom, D., Bird, L., Christie, A. L., Christodoulou, A., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711176 · Cited by 45
Shen, P., Wang, Y., Jia, X., Xu, P., Qin, L., Feng, X., Li, Z., & Qiu, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114551 · Cited by 45
Axelrod, M. J., Ou, Z., Brett, L. K., Zhang, L., Lopez, E., Tamayo, A., Gordon, V. L., Ford, R. J., Williams, M. E., Pham, L. V., et al. (2013) · Leukemia · doi:10.1038/leu.2013.249 · Cited by 46
Self-citationHow to manage mantle cell lymphoma
Dreyling, M. H., Ferrero, S., & Hermine, O. (2014) · Leukemia · doi:10.1038/leu.2014.171 · Cited by 46
Self-citationCD79B limits response of diffuse large B cell lymphoma to ibrutinib
Kim, J. H., Kim, W. S., Ryu, K. J., Kim, S. J., & Park, C. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1113276 · Cited by 45
Viganego, F., Singh, R., & Fradley, M. G. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0730-0 · Cited by 45
Autoimmunity checkpoints as therapeutic targets in B cell malignancies
Müschen, M. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.111 · Cited by 48
Singer, S. B., Tan, S., Dewan, A. K., Davids, M. S., LaCasce, A. S., Treon, S. P., & LeBoeuf, N. R. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.031 · Cited by 45
Liu, M., Deng, H., Mu, J., Li, Q., Pu, Y., Jiang, Y., Deng, Q., & Qian, Z. (2021) · Cancer Science · doi:10.1111/cas.14915 · Cited by 45
Thorp, B. C., & Badoux, X. C. A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1339874 · Cited by 44
Chen, J., Kinoshita, T., Gururaja, T. L., Sukbuntherng, J., James, D. F., Lu, D., Whang, J. A., Versele, M., & Chang, B. Y. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13148 · Cited by 46
Self-citationAuranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
Hu, J., Zhang, H., Cao, M., Wang, L., Wu, S., & Fang, B. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1173 · Cited by 46
Self-citationBair, S. M., Brandstadter, J. D., Ayers, E. C., & Stadtmauer, E. A. (2020) · Cancer · doi:10.1002/cncr.32659 · Cited by 45
Ibrutinib for the Treatment of Mantle Cell Lymphoma
Herrera, A. F., & Jacobsen, E. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0010 · Cited by 43
Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors
Reinwald, M., Boch, T., Hofmann, W., & Buchheidt, D. (2015) · Biomarker Insights · doi:10.4137/bmi.s22430 · Cited by 45
Metadata
- Authors
- Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., & Blum, K. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Derriford Hospital (GB)
- Weill Cornell Medicine (US)
- Hackensack University Medical Center (US)
- University of Wisconsin–Madison (US)
- Jagiellonian University (PL)
- Stanford Medicine (US)
- University of Virginia (US)
- Northwell Health (US)
- Centrum Onkologii (PL)
- University of Manchester (GB)
- University Hospital Ulm (DE)
- LMU Klinikum (DE)
- Cancer Research UK (GB)
- Oregon Health & Science University (US)
- Pharmacyclics (United States) (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- ORCID
- Wang, Michael L.
- Rule, Simon
- Martin, Peter
- Goy, Andre
- Auer, Rebecca
- Kahl, Brad S.
- Jurczak, Wojciech
- Advani, Ranjana H.
- Romaguera, Jorge E.
- Williams, Michael E.
- Barrientos, Jacqueline C.
- Radford, John
- Stilgenbauer, Stephan
- Dreyling, Martin
- Johnson, Peter
- Spurgeon, Stephen E.
- Li, Lei
- Zhang, Liang
- Newberry, Kate
- Fang, Bingliang
- Chang, Betty Y.
- Blum, Kristie A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-08
- Volume
- 369
- Issue
- 6
- Pages
- 507-516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4513941
- OpenAlex
- W2154066874
- Cited by
- 1,685
- References
- 39
- Citations by year
- 2026: 59 · 2025: 67 · 2024: 91 · 2023: 115 · 2022: 142 · 2021: 127 · 2020: 138 · 2019: 127 · 2018: 141 · 2017: 161 · 2016: 133 · 2015: 189 · 2014: 147 · 2013: 42
- FWCI
- 127.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Society of Hematology
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Celgene
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Genentech
- Pharmacyclics
- National Cancer Institute (P30CA014520)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- ibrutinib, BTK inhibitors, mantle cell lymphoma, relapsed/refractory lymphoma, bortezomib, B cell receptor signaling, oral BTK inhibitor, overall response rate, progression-free survival, overall survival, adverse events, neutropenia
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Analysis, Lymphocyte Count, Drug Resistance, Neoplasm, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
